Ayala Pharmaceuticals Stock Working Capital
| ADXSDelisted Stock | USD 1.38 0.34 32.69% |
Ayala Pharmaceuticals fundamentals help investors to digest information that contributes to Ayala Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ayala OTC Stock. The fundamental analysis module provides a way to measure Ayala Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ayala Pharmaceuticals otc stock.
Ayala |
Ayala Pharmaceuticals OTC Stock Working Capital Analysis
Ayala Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Ayala Pharmaceuticals Working Capital | 132.17 M |
Most of Ayala Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ayala Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, Ayala Pharmaceuticals has a Working Capital of 132.17 M. This is 68.95% lower than that of the Healthcare sector and 75.46% lower than that of the Biotechnology industry. The working capital for all United States stocks is 91.06% higher than that of the company.
Ayala Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ayala Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Ayala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ayala Pharmaceuticals by comparing valuation metrics of similar companies.Ayala Pharmaceuticals is currently under evaluation in working capital category among its peers.
Ayala Fundamentals
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 | ||||
| Current Valuation | (25.1 M) | ||||
| Shares Outstanding | 145.64 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 39.89 K | ||||
| Price To Earning | (1.62) X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 990.34 X | ||||
| Revenue | 250 K | ||||
| Gross Profit | 3.24 M | ||||
| EBITDA | (15.31 M) | ||||
| Net Income | (16.24 M) | ||||
| Cash And Equivalents | 28.15 M | ||||
| Cash Per Share | 15.50 X | ||||
| Total Debt | 19 K | ||||
| Current Ratio | 15.64 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (16.04 M) | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.28 | ||||
| Market Capitalization | 247.58 M | ||||
| Total Asset | 169.04 M | ||||
| Retained Earnings | (354.94 M) | ||||
| Working Capital | 132.17 M | ||||
| Current Asset | 159.88 M | ||||
| Current Liabilities | 27.71 M |
About Ayala Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ayala Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ayala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ayala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Ayala OTC Stock
If you are still planning to invest in Ayala Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ayala Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets |